FDA Says Abbott Medical Issues Correction For HeartMate LVAS System Monitor Due To Screen Issues That Could Cause Unintentional Pump Stop
Portfolio Pulse from Benzinga Newsdesk
The FDA has announced that Abbott Medical has issued a correction for its HeartMate LVAS System Monitor due to screen issues that could potentially cause an unintentional pump stop.
June 28, 2024 | 6:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Abbott Medical has issued a correction for its HeartMate LVAS System Monitor due to screen issues that could cause unintentional pump stops, as announced by the FDA.
The correction issued by Abbott Medical for the HeartMate LVAS System Monitor due to potential safety issues is likely to negatively impact investor sentiment in the short term. Regulatory actions and product corrections often lead to concerns about product reliability and potential financial implications.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100